BERLIN, Could 4 (Reuters) – U.S.-German medical gadget maker Siemens Healthineers (SHLG.DE) raised its targets for the 2022 monetary 12 months on Wednesday as a result of elevated demand for speedy COVID-19 antigen exams, and reported an increase in second-quarter income and earnings.
The corporate stated it now anticipated its diagnostics phase to generate round 1.3 billion euros ($1.37 billion) in income with speedy COVID-19 antigen exams, up from some 700 million euros beforehand.
Because of this, it anticipated comparable income progress of between 5.5% and seven.5%, up from 3% to five% beforehand, and adjusted primary earnings per share of between 2.25 and a pair of.35 euros, up from 2.18 to 2.30 euros beforehand.
Register now for FREE limitless entry to Reuters.com
“Our enterprise continues to indicate nice resilience within the face of unprecedented challenges. On this basis, and because of excessive demand for our speedy antigen exams, we’re elevating our outlook for the present monetary 12 months,” CEO Bernd Montag stated.
($1 = 0.9510 euros)
(This story corrects to indicate income rose in second quarter, not first quarter, of 2022 monetary 12 months in paragraph 1)
Register now for FREE limitless entry to Reuters.com
Writing by Paul Carrel, Enhancing by Miranda Murray
Our Requirements: The Thomson Reuters Trust Principles.
